NexImmune, Inc. (NEXI) News & Overview - Discounting Cash Flows
NEXI
NexImmune, Inc.
NEXI (OTC)

NEXI's Business Model

NexImmune, Inc., a clinical-stage biotechnology company, engages in developing therapies with curative potential for patients with cancer and other life-threatening immune-mediated diseases. It develops approaches to T cell immunotherapies based on its proprietary Artificial Immune Modulation, a nanoparticle technology platform. The company's product candidates include NEXI-001, an allogeneic cell therapy, which is in Phase I/II clinical trials for the treatment of patients with acute myeloid leukemia; NEXI-002, an autologous cell therapy that is in Phase I/II clinical trials for the treatment of patients with relapsed and/or refractory in multiple myeloma; and NEXI-003, a candidate targeted against HPV-associated malignancies, which is in preclinical stage. NexImmune, Inc. was incorporated in 2011 and is headquartered in Gaithersburg, Maryland.
Sector & Industry Healthcare / Biotechnology
Website https://www.neximmune.com
CEO (Chief Executive Officer) John Trainer
Number of Employees
IPO date February 12, 2021

NEXI Latest News

Contact
CountryUS
Address9119 Gaither Road
CityGaithersburg
StateMD
Phone301 825 9810
Zip Code20877
Other Identifiers
CIK0001538210
ISINUS65344D2080
CUSIP65344D109
Open0.0001
Previous Close0.0001
Volume500
Average Volume283
Day’s Range0.0001 – 0.0001
52 Week Range0.0001-2.95
MA (50)0.0001
MA (200)0.10245
Market Cap139
Shares Out.1.39 Mil.
Earnings DateAug 05, 2025
Beta
Last Dividend
EPS
PE

Industry Competitors for NEXI

discounting cash flows home logo

Discounting Cash Flows

Are you finding our services helpful? Review us on trustpilot logo Trustpilot
Have a question? Contact us